

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- may not be able to do strenuous activity but able to walk and do work of a light or sedentary nature, e.g., light house work, office work - advanced or metastatic cancer who have previously been treated - see link to clinicaltrials.gov for complete Inclusion Criteria

Exclusion Criteria:

- active autoimmune or immunodeficiency disease - women who are pregnant - significant heart disease - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Colorectal Cancer, Gastric/Esophageal Cancer, Head and Neck Carcinoma, Serous Ovarian Cancer

More Information

Description: This trial will evaluate whether azirkitug (ABBV-514) as monotherapy and in combination with budigalimab (ABBV-181) or bevacizumab is safe and tolerable for people with locally advanced or metastatic solid tumors.

Study Contact: Naomi Fujioka - fujio002@umn.edu

Principal Investigator: Naomi Fujioka

Phase: PHASE1

IRB Number: STUDY00026235

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.